Cyril H. Benes publications per year

The chart shows the history of publications by Cyril H. Benes between 1997 and 2025, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Cyril H. Benes published across 29 years, from 1997 to 2025, averaging 23.8 papers a year. Output peaked at 397 publications in 2023. 31 of the 689 publications appeared in the last two years.

No. of publications

100 200 300

1997 2025

689 publications in total across all disciplines

View publications per year as a table

Cyril H. Benes: publications per year, 1997 to 2025
Year	Publications
1997	2
1998	1
1999	1
2000	1
2001	1
2002	2
2003	0
2004	1
2005	2
2006	0
2007	0
2008	1
2009	3
2010	0
2011	11
2012	14
2013	26
2014	21
2015	19
2016	23
2017	31
2018	39
2019	30
2020	13
2021	11
2022	8
2023	397
2024	5
2025	26
Total	689

Download as CSV

Cyril H. Benes publication distribution in Molecular Biology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Molecular Biology in 2026. The highlighted bar marks where Cyril H. Benes sits on this spectrum.

No. of scientists

50 100 150

47–56 publications 564+

This scientist: 374 publications — 89th percentile

89% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 564 publications or more.

View publications distribution as a table

Number of Molecular Biology scientists by publication count, Research.com 2026 ranking edition. Based on 3,076 ranked scientists.
Publications	Scientists	This scientist
47–56	7
57–66	17
67–76	65
77–86	90
87–96	125
97–106	131
107–116	162
117–126	177
127–136	158
137–146	158
147–156	146
157–166	159
167–176	131
177–186	110
187–196	112
197–206	100
207–216	89
217–226	98
227–236	74
237–246	72
247–256	63
257–266	53
267–276	54
277–286	49
287–296	52
297–306	43
307–316	46
317–326	41
327–336	42
337–346	31
347–356	28
357–366	29
367–376	26	374
377–386	24
387–396	24
397–406	14
407–416	13
417–426	20
427–436	12
437–446	20
447–456	11
457–466	10
467–476	14
477–486	14
487–496	10
497–506	13
507–516	13
517–526	2
527–536	4
537–546	6
547–556	8
557–563	6
564+	100

Download as CSV

Cyril H. Benes D-index placement in Molecular Biology in 2026

The chart shows the D-index (discipline H-index) distribution of Molecular Biology scientists ranked by Research.com in 2026. The highlighted bar marks where Cyril H. Benes sits on this spectrum.

No. of scientists

25 50 75 100 125

40–41 D-Index 145+

This scientist: 75 D-Index — 62nd percentile

62% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 145 D-Index or more.

View D-Index distribution as a table

Number of Molecular Biology scientists by D-index, Research.com 2026 ranking edition. Based on 3,076 ranked scientists.
D-Index	Scientists	This scientist
40–41	36
42–43	101
44–45	115
46–47	121
48–49	118
50–51	130
52–53	106
54–55	116
56–57	113
58–59	129
60–61	120
62–63	105
64–65	131
66–67	95
68–69	97
70–71	106
72–73	83
74–75	89	75
76–77	77
78–79	70
80–81	73
82–83	60
84–85	48
86–87	45
88–89	50
90–91	31
92–93	51
94–95	43
96–97	38
98–99	39
100–101	41
102–103	29
104–105	33
106–107	35
108–109	20
110–111	38
112–113	19
114–115	28
116–117	13
118–119	23
120–121	16
122–123	15
124–125	11
126–127	21
128–129	7
130–131	13
132–133	14
134–135	17
136–137	9
138–139	8
140–141	16
142–143	7
144	7
145+	100

Download as CSV

Overview

Cyril H. Benes is a researcher affiliated with Harvard University in the United States. Their work spans the fields of Biochemistry, Genetics and Molecular Biology, and Medicine, with a significant focus on Molecular Biology, Oncology, Cancer Research, Computational Theory and Mathematics, and Cell Biology.

Their research investigates multiple aspects of cancer biology and therapeutics, particularly emphasizing cancer genomics and diagnostics, computational drug discovery methods, RNA modifications related to cancer, neuroblastoma research and treatments, cancer hypoxia and metabolism, ubiquitin and proteasome pathways, and mechanisms underlying cancer therapeutics.

Recent published papers by Cyril H. Benes include:

Effective drug combinations in breast, colon and pancreatic cancer cells (2022, Nature)
Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms (2021, Cancer Cell)
MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer (2020, Clinical Cancer Research)
Pharmacological blockade of TEAD-YAP reveals its therapeutic limitation in cancer cells (2022, Nature Communications)
Therapy-induced APOBEC3A drives evolution of persistent cancer cells (2023, Nature)

Frequent co-authors who have collaborated with Cyril H. Benes include:

Patricia Greninger
Regina K. Egan
Ellen Murchie
Mikhail G. Dozmorov
Anthony C. Faber

Common venues where Cyril H. Benes has published encompass:

Cancer Research
bioRxiv (Cold Spring Harbor Laboratory)
Nature Communications
Molecular Cancer Therapeutics
Nature

Best Publications

Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells

Wanjuan Yang;Jorge Soares;Patricia Greninger;Elena J. Edelman

3321
Citations
Systematic identification of genomic markers of drug sensitivity in cancer cells

Mathew J. Garnett;Elena J. Edelman;Sonja J. Heidorn;Christopher Greenman;Christopher Greenman

2736
Citations
A Landscape of Pharmacogenomic Interactions in Cancer

Francesco Iorio;Francesco Iorio;Theo A. Knijnenburg;Theo A. Knijnenburg;Daniel J. Vis;Graham R. Bignell

2122
Citations
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

Ryohei Katayama;Alice T. Shaw;Alice T. Shaw;Tahsin M. Khan;Tahsin M. Khan;Mari Mino-Kenudson

1425
Citations
Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility

Min Yu;Min Yu;Aditya Bardia;Nicola Aceto;Francesca Bersani

975
Citations
Targeting transcription regulation in cancer with a covalent CDK7 inhibitor

Nicholas Kwiatkowski;Tinghu Zhang;Peter B. Rahl;Brian J Abraham

846
Citations
Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition

Alexandre Puissant;Stacey M. Frumm;Gabriela Alexe;Christopher F. Bassil

686
Citations
Pharmacogenomic agreement between two cancer cell line data sets

Nicolas Stransky;Mahmoud Ghandi

538
Citations
Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors

Rachel Litman Flynn;Rachel Litman Flynn;Kelli E. Cox;Maya Jeitany;Hiroaki Wakimoto

514
Citations
Stromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic Cancer

Matteo Ligorio;Srinjoy Sil;Jose Malagon-Lopez;Linda T. Nieman

440
Citations
Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models.

Ryan B. Corcoran;Katherine A. Cheng;Aaron N. Hata;Anthony C. Faber

411
Citations
HER2 expression identifies dynamic functional states within circulating breast cancer cells

Nicole Vincent Jordan;Aditya Bardia;Ben S. Wittner;Cyril Benes

398
Citations
AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies.

Sean Caenepeel;Sean P Brown;Brian Belmontes;Gordon Moody

389
Citations
ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells.

Stephanie A. Yazinski;Valentine Comaills;Rémi Buisson;Marie Michelle Genois

348
Citations
BIM expression in treatment naïve cancers predicts responsiveness to kinase inhibitors

Anthony C. Faber;Ryan B. Corcoran;Hiromichi Ebi;Lecia V. Sequist

321
Citations
TAK1 Inhibition Promotes Apoptosis in KRAS-Dependent Colon Cancers

Anurag Singh;Michael F. Sweeney;Min Yu;Alexa Burger

314
Citations
Distinct but Concerted Roles of ATR, DNA-PK, and Chk1 in Countering Replication Stress during S Phase.

Rémi Buisson;Jessica L. Boisvert;Cyril H. Benes;Lee Zou

313
Citations
The C2 domain of PKCdelta is a phosphotyrosine binding domain.

Cyril H. Benes;Ning Wu;Andrew E.H. Elia;Tejal Dharia

309
Citations
TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion–Positive Intrahepatic Cholangiocarcinoma

Lipika Goyal;Lei Shi;Leah Y Liu;Ferran Fece de la Cruz

307
Citations
Passenger hotspot mutations in cancer driven by APOBEC3A and mesoscale genomic features

Rémi Buisson;Rémi Buisson;Adam Langenbucher;Danae Bowen;Eugene E. Kwan

276
Citations

Frequent Co-Authors

Mathew J. Garnett Wellcome Sanger Institute

Jeffrey A. Engelman Novartis Institutes for BioMedical Research (NIBR)

Ultan McDermott AstraZeneca (United Kingdom)

Daniel A. Haber Harvard University

Olivier Elemento Cornell University

Wafik S. El-Deiry Brown University

Jeffrey Settleman Pfizer (Germany)

Alice T. Shaw Harvard University

Sridhar Ramaswamy Harvard University

Lecia V. Sequist Harvard University

If you think any of the details on this page are incorrect, let us know.

Related Online Degrees & Career Pathways

If you’re considering a future in molecular biology, exploring related online degrees can open doors to diverse career pathways. Many students look for flexible learning options that align with their professional goals and lifestyles. For example, programs like capella rn to bsn vs chamberlain rn to bsn highlight how different institutions offer varied curriculum structures and support services, which is important to consider when choosing an online degree.

For those considering an advanced healthcare path, there are accessible online bsn programs available, often featuring accelerated tracks and affordable tuition. Finding a reputable school is critical for a quality education—many students prefer nonprofit online colleges that offer accredited programs with solid student support.

If you’re an active-duty military member or veteran, you might prioritize flexible scheduling and tuition assistance. Several academic institutions offer dedicated resources for service members, and some of the best in the country are recognized as top online military friendly colleges.